Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that patients with lupus nephritis experience a greater overall burden than those with systemic lupus erythematosus without nephritis, particularly impacting areas such as family planning, professional life, disease features, medication usage, and quality of life.

In this study, ritlecitinib 50-mg showed clinically meaningful efficacy, with improvements in the Severity of Alopecia Tool score observed in patients with alopecia areata over a 3-year period, demonstrating long-term benefit in both clinician- and patient-reported outcomes.

This study explored a mother and daughter with loose anagen hair syndrome linked to wooly hair, identifying an intronic variant in the KRT71 gene that affects hair keratin splicing, thus broadening the spectrum of KRT71-related disorders.

This study found that RNase L acts as a regeneration repressor gene in mammals, as seen in Rnasel-/- mice which showed increased regenerative capacity and elevated Wound Induced Hair Neogenesis through enhanced IL-36α signaling, suggesting a tradeoff between regeneration and immune regulation.

In this study, lichen striatus was the most common linear dermatosis observed, with most lesions occurring along Blaschko’s lines, and histopathological evaluation often revealed different underlying conditions.

This case report presents a 2-year-old girl with type B loose anagen syndrome diagnosed through a painless hair pull test, avoiding unnecessary further tests or referrals.

This case report describes a 2-year-old girl with loose anagen syndrome type B, confirmed by painless trichoscopic examination, with no signs in her identical twin sister.

Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.

This review discusses loose anagen hair syndrome in children, characterized by non-scarring alopecia and increased hair shedding, and reports no new results; topical minoxidil may be used as a treatment.

This audit of ritlecitinib prescribing for severe alopecia areata found that regional practices largely followed national guidelines but highlighted the need for better psychological assessments and more consistent use of SALT scoring to inform treatment continuation decisions after 36 weeks.

This study evaluated the real-world use of ritlecitinib for severe alopecia areata in the UK, reporting that 37% of patients achieved significant hair regrowth by week 36, with no serious adverse effects noted, although response varied with disease duration.

This study found that patients with lichen sclerosus et atrophicus who have autoimmune-related phenomena do not experience a different natural history of the disease compared to those without such phenomena.

This report describes a case of juvenile Rhupus syndrome in an 11-year-old girl, emphasizing the condition's rarity and the diagnostic challenges due to overlapping symptoms of juvenile idiopathic arthritis and systemic lupus erythematosus.

In this study, ritlecitinib 50 mg produced clinically meaningful improvements in scalp hair regrowth over three years for patients aged 12 and older with severe alopecia areata, with 65.1% showing substantial hair regrowth and 31.2% achieving complete regrowth, while also maintaining a consistent safety profile.

This study found that low-level laser therapy (LLLT) may enhance hearing recovery after noise-induced hearing loss in rats.

In this study, researchers found that retinoids might improve lupus nephritis resistant to conventional treatments, but the sample size was too small for significant results, and side effects were noted.

This review highlights the emerging role of long non-coding RNAs (lncRNAs) in dermatology, suggesting that lncRNAs significantly impact signaling pathways involved in normal skin functions and skin diseases, offering potential as biomarkers and therapeutic targets.

This study reports that a patient with rare linear lichen planopilaris experienced complete hair regrowth after 12 weeks of treatment with the antibody ixekizumab, suggesting it as a potential targeted therapy.

This study found that a phosphorus starvation-insensitive mutant of Arabidopsis thaliana shows altered root growth and auxin responses under low phosphate conditions compared to wild-type plants, suggesting a role for LPR1 in regulating these traits.

In this prospective study, ritlecitinib effectively reduced hair loss in patients with severe alopecia areata, with 43.3% of participants achieving a 20 or lower SALT score by week 24, and showed a good midterm safety profile.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

This study suggests that the EULAR/ACR classification criteria for SLE may help predict organ damage, particularly in renal, cardiovascular, dermatological, and gonadal domains.

This article describes a non-blinded study investigating low level laser therapy for seven patients but reports no new clinical findings.

This review discusses the diagnostic criteria and guidelines for managing loose anagen syndrome and differentiating it from non-scarring alopecias, but it reports no new clinical results.

This case report highlights the complexity of lupus erythematosus/lichen planus overlap syndrome, noting a high potential for progression to systemic lupus erythematosus.

This source reports that a comprehensive review of LSS gene variant phenotypes enhances understanding of congenital hypotrichosis 14 and could guide more precise genetic counseling and future research into disease mechanisms and potential therapies.

This study by Arthritis Ireland highlights that individuals living with lupus in Ireland face widespread impacts on daily life, work, and mental health, with 70% experiencing frequent flares despite 93% being on medication; 45% also reported significant medication side effects.

In this study, real-world data of 31 patients using ritlecitinib for severe alopecia areata showed that 51% achieved significant hair regrowth after one year, with no serious adverse events reported, emphasizing the importance of considering treatment duration for response.

In this study, participants receiving a 50-mg maintenance dose of ritlecitinib reported greater improvements in emotional and activity limitations due to hair loss by Week 48 compared to those on a 10-mg dose.